Cancer Associated Fibroblast (CAF) Regulation of PDAC Parenchymal (CPC) and CSC Phenotypes Is Modulated by ECM Composition.

3D organotypic cultures desmoplastic reaction invadopodia pancreatic ductal adenocarcinoma vasculogenic mimicry

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
31 Jul 2022
Historique:
received: 27 06 2022
revised: 25 07 2022
accepted: 27 07 2022
entrez: 12 8 2022
pubmed: 13 8 2022
medline: 13 8 2022
Statut: epublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of all cancers, having one of the lowest five-year survival rates. One of its hallmarks is a dense desmoplastic stroma consisting in the abnormal accumulation of extracellular matrix (ECM) components, especially Collagen I. This highly fibrotic stroma embeds the bulk cancer (parenchymal) cells (CPCs), cancer stem cells (CSCs) and the main producers of the stromal reaction, the Cancer Associated Fibroblasts (CAFs). Little is known about the role of the acellular ECM in the interplay of the CAFs with the different tumor cell types in determining their phenotypic plasticity and eventual cell fate. Here, we analyzed the role of ECM collagen I in modulating the effect of CAF-derived signals by incubating PDAC CPCs and CSCs grown on ECM mimicking early (low collagen I levels) and late (high collagen I levels) stage PDAC stroma with conditioned medium from primary cultured CAFs derived from patients with PDAC in a previously described three-dimensional (3D) organotypic model of PDAC. We found that CAFs (1) reduced CPC growth while favoring CSC growth independently of the ECM; (2) increased the invasive capacity of only CPCs on the ECM mimicking the early tumor; and (3) favored vasculogenic mimicry (VM) especially of the CSCs on the ECM mimicking an early tumor. We conclude that the CAFs and acellular stromal components interact to modulate the tumor behaviors of the PDAC CPC and CSC cell types and drive metastatic progression by stimulating the phenotypic characteristics of each tumor cell type that contribute to metastasis.

Sections du résumé

BACKGROUND BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of all cancers, having one of the lowest five-year survival rates. One of its hallmarks is a dense desmoplastic stroma consisting in the abnormal accumulation of extracellular matrix (ECM) components, especially Collagen I. This highly fibrotic stroma embeds the bulk cancer (parenchymal) cells (CPCs), cancer stem cells (CSCs) and the main producers of the stromal reaction, the Cancer Associated Fibroblasts (CAFs). Little is known about the role of the acellular ECM in the interplay of the CAFs with the different tumor cell types in determining their phenotypic plasticity and eventual cell fate.
METHODS METHODS
Here, we analyzed the role of ECM collagen I in modulating the effect of CAF-derived signals by incubating PDAC CPCs and CSCs grown on ECM mimicking early (low collagen I levels) and late (high collagen I levels) stage PDAC stroma with conditioned medium from primary cultured CAFs derived from patients with PDAC in a previously described three-dimensional (3D) organotypic model of PDAC.
RESULTS RESULTS
We found that CAFs (1) reduced CPC growth while favoring CSC growth independently of the ECM; (2) increased the invasive capacity of only CPCs on the ECM mimicking the early tumor; and (3) favored vasculogenic mimicry (VM) especially of the CSCs on the ECM mimicking an early tumor.
CONCLUSIONS CONCLUSIONS
We conclude that the CAFs and acellular stromal components interact to modulate the tumor behaviors of the PDAC CPC and CSC cell types and drive metastatic progression by stimulating the phenotypic characteristics of each tumor cell type that contribute to metastasis.

Identifiants

pubmed: 35954400
pii: cancers14153737
doi: 10.3390/cancers14153737
pmc: PMC9367491
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fondation de France
ID : 2013-00038330; 2015-00059283
Organisme : Fondation ARC pour la Recherche sur le Cancer
ID : PJA 20161204740
Organisme : Ligue contre le Cancer
ID : GB/MA/IQ-10607
Organisme : Marie Skłodowska-Curie
ID : No. 813834-pHioniC-H2020-MSCA-ITN-2018
Organisme : Marie Curie Initial Training Network IonTraC
ID : FP7-PEOPLE-2011-ITN Grant Agreement No. 289648

Références

J Hematol Oncol. 2017 Mar 28;10(1):76
pubmed: 28351381
Cancer Res. 2008 Feb 1;68(3):918-26
pubmed: 18245495
Int J Oncol. 2016 Jul;49(1):243-52
pubmed: 27177201
Cell. 2018 Feb 8;172(4):841-856.e16
pubmed: 29395328
Cancers (Basel). 2021 Sep 03;13(17):
pubmed: 34503252
Pancreas. 2010 May;39(4):425-35
pubmed: 20418756
Mol Cells. 2014 Dec 31;37(12):888-98
pubmed: 25518923
FEBS J. 2018 Jun;285(11):2104-2124
pubmed: 29660229
World J Gastrointest Oncol. 2016 Jan 15;8(1):55-66
pubmed: 26798437
PLoS One. 2017 Nov 30;12(11):e0188870
pubmed: 29190794
Cell. 2012 Jan 20;148(1-2):349-61
pubmed: 22265420
Oncol Rep. 2017 Apr;37(4):1971-1979
pubmed: 28260082
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Nat Commun. 2017 Jul 07;8:16031
pubmed: 28685754
Cancers (Basel). 2021 Dec 06;13(23):
pubmed: 34885243
Int J Dev Biol. 2011;55(4-5):477-82
pubmed: 21732274
Genes Dev. 2016 Feb 15;30(4):355-85
pubmed: 26883357
Int J Oncol. 2015 Mar;46(3):1099-108
pubmed: 25502497
J Cell Biochem. 2007 Jul 1;101(4):887-907
pubmed: 17266048
Cancer Res. 2017 Apr 15;77(8):2134-2147
pubmed: 28202523
Chin Clin Oncol. 2017 Dec;6(6):59
pubmed: 29307199
Front Oncol. 2021 Oct 06;11:751311
pubmed: 34692532
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1129-1134
pubmed: 28096419
Front Physiol. 2014 Apr 09;5:141
pubmed: 24782785
Neoplasia. 2015 Feb;17(2):155-66
pubmed: 25748234
Cancers (Basel). 2014 Oct 21;6(4):2137-54
pubmed: 25337831
Cancer Res. 2006 May 1;66(9):4662-71
pubmed: 16651417
Int J Mol Sci. 2020 Dec 22;22(1):
pubmed: 33375106
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188418
pubmed: 32827581
J Biol Chem. 2011 Mar 25;286(12):10495-504
pubmed: 21288898
Transl Oncol. 2017 Aug;10(4):578-588
pubmed: 28658650
Exp Cell Res. 2017 Aug 1;357(1):79-87
pubmed: 28461158
J Clin Invest. 2016 Nov 1;126(11):4140-4156
pubmed: 27701147
Cancers (Basel). 2018 Jan 26;10(2):
pubmed: 29373514
Surg Oncol. 2015 Sep;24(3):232-8
pubmed: 26080604
Cancers (Basel). 2018 Jan 27;10(2):
pubmed: 29382042
Semin Cell Dev Biol. 2018 Jun;78:62-72
pubmed: 28673679
FASEB J. 2010 Oct;24(10):3903-15
pubmed: 20547664
Arch Pathol Lab Med. 2011 Jun;135(6):716-27
pubmed: 21631264
Clin Cancer Res. 2015 Aug 1;21(15):3561-8
pubmed: 25695692

Auteurs

Stefania Cannone (S)

Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy.

Maria Raffaella Greco (MR)

Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy.

Tiago M A Carvalho (TMA)

Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy.

Helene Guizouarn (H)

Institute of Biology de Valrose, CNRS UMR 7277, University of Nice, 06108 Nice, France.

Olivier Soriani (O)

Institute of Biology de Valrose, CNRS UMR 7277, University of Nice, 06108 Nice, France.

Daria Di Molfetta (D)

Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy.

Richard Tomasini (R)

INSERM, U1068, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, CNRS, UMR7258, 13009 Marseille, France.

Katrine Zeeberg (K)

Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy.

Stephan Joel Reshkin (SJ)

Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy.

Rosa Angela Cardone (RA)

Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, 70126 Bari, Italy.

Classifications MeSH